GAO Report Gives FDA Flunking Grade in Detecting Drug Dangers

“More than a year after the Food and Drug Administration announced it had strengthened its drug safety system, the agency still lacks a reliable system for keeping track of emerging problems, congressional investigators concluded in a report to be released today.” [Los Angeles Times, below]

Continue reading →

Disease Mongering_Conference / PLoS Special Issue

"Are we becoming patients for profit? That is the question knowledgeable observers are asking. Continue reading →

Big Pharma’s Shameful Secret

"Every year, drug companies spend $14 billion to test experimental substances on humans. Across the U.S., the centers that do the testing–and the regulators who watch them–allow scores of human test subjects to be injured or killed."

Continue reading →

Testimony of Meryl Nass, MD – Senate HELP Committee, Subcommittee on Bioterrorism

Thank you for the opportunity to submit this testimony for the record.

My name is Meryl Nass, M.D., and I have worked for the past twenty years as an emergency physician and internist in community hospitals in the northeastern US. I have also studied many aspects of bioterrorism since 1989. I am the person who first demonstrated, in 1992, that one could investigate an epidemic retrospectively, and prove that it was due to biological warfare, using Rhodesia’s 1978-80 anthrax epidemic as a model.[1]

Continue reading →

Conflicts of Interest in Clinical Trials

Presented by Vera Hassner Sharav
14th Tri-Service Clinical Investigation Symposium
Sponsored by The U.S. Army Medical Department and The Henry M. Jackson Foundation for the Advancment of Military Medicine

The cornerstone of public trust in medical research is the integrity of academic institutions and the expectation that universities, which rely on public funding, have a responsibility to serve the public good. Financial conflicts of interest affect millions of American people – those who are subjects of clinical trials testing new drugs and those who are prescribed drugs after their approval. Continue reading →

Sharav Presentation before US Army Medical Dept., May 6, 2002

CONFLICTS OF INTEREST Presented by Vera Hassner Sharav 14th TRI-SERVICE CLINICAL INVESTIGATION SYMPOSIUM Sponsored By THE U.S. ARMY MEDICAL DEPARTMENT And THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCMENT OF MILITARY MEDICINE May 5-7, 2002 The cornerstone of public trust in medical . . . Continue reading →

InfoMail for February 19, 2002

  AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav February 19, 2002 How a New FDA Policy Led toSeven Deadly Drugs FYI The Seattle Times reports, "Therelationship between the . . . Continue reading →